Literature DB >> 34283399

Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.

Anil Aysal1, Cihan Agalar2, Tufan Egeli2, Tarkan Unek2, Ilhan Oztop3, Funda Obuz4, Ozgul Sagol5.   

Abstract

The question of how successful we are in predicting pancreatic neuroendocrine tumors (panNET) with poor prognosis has not been fully answered yet. The aim of this study was to investigate the effects of clinicopathological features on prognosis and to determine their validity in prediction of prognosis and whether a better prognostic classification can be made. Fifty-six patients who underwent pancreatic resection for pancreatic neuroendocrine tumor were included. The associations between clinicopathological parameters and prognosis were evaluated statistically. Efficiencies of different thresholds for tumor size, mitotic count, and Ki67 proliferation index for prognosis prediction were compared. Vascular invasion was statistically associated with high tumor grade, advanced pT stage, and mortality rate. The presence of non-functional tumor, lymphatic invasion, and > 10 cm tumor size were significantly related to shorter overall survival. Advanced pT stage (pT3-4), > 5 cm tumor size, and high tumor grade (grades 2-3) were significantly associated with shorter disease-free survival. The mortality rate showed the strongest statistical significance with mitotic count when grouped as 1: < 2, 2: 2-10, and 3: > 10 mitosis/ 2 mm2. The 10% threshold value for Ki67 index was more successful in predicting adverse prognosis. Among the morphologic variants, the ductulo-insular variant was the most promising to have positive prognostic value in our series, although no statistical significance was detected. In conclusion, threshold values of 5 cm and 10 cm for tumor size, 10% for Ki67 proliferation index, and 10/2 mm2 for mitotic count and vascular and lymphatic invasion assessed separately are potential prognostic candidates for better stratification of panNETs.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Mitosis; Morphologic variant; Neuroendocrine tumor; Pancreas; Prognosis; Tumor grade; Tumor size; Vascular invasion

Mesh:

Substances:

Year:  2021        PMID: 34283399     DOI: 10.1007/s12022-021-09687-w

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  24 in total

1.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

2.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

3.  Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Mod Pathol       Date:  2011-07-29       Impact factor: 7.842

Review 4.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

5.  Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies.

Authors:  Michelle D Reid; Pelin Bagci; Nobuyuki Ohike; Burcu Saka; Ipek Erbarut Seven; Nevra Dursun; Serdar Balci; Hasan Gucer; Kee-Taek Jang; Takuma Tajiri; Olca Basturk; So Yeon Kong; Michael Goodman; Gizem Akkas; Volkan Adsay
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

Review 6.  Neuroendocrine tumors of the pancreas: current concepts and controversies.

Authors:  Michelle D Reid; Serdar Balci; Burcu Saka; N Volkan Adsay
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

7.  Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.

Authors:  F Ausania; P Senra Del Rio; M A Gomez-Bravo; E Martin-Perez; J A Pérez-Daga; D Dorcaratto; T González-Nicolás; S Sanchez-Cabus; A Tardio-Baiges
Journal:  Pancreatology       Date:  2019-01-19       Impact factor: 3.996

8.  Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.

Authors:  Yue Xue; Michelle D Reid; Burcin Pehlivanoglu; Rebecca C Obeng; Hongmei Jiang; Bahar Memis; Shu K Lui; Juan Sarmiento; David Kooby; Shishir K Maithel; Bassel El-Rayes; Olca Basturk; Volkan Adsay
Journal:  Endocr Pathol       Date:  2020-09       Impact factor: 3.943

Review 9.  A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.

Authors:  Jiayun M Fang; Jiaqi Shi
Journal:  Arch Pathol Lab Med       Date:  2019-09-11       Impact factor: 5.534

10.  Life expectancy in pancreatic neuroendocrine cancer.

Authors:  Jordan C Brooks; Robert M Shavelle; Kate N Vavra-Musser
Journal:  Clin Res Hepatol Gastroenterol       Date:  2018-09-13       Impact factor: 2.947

View more
  1 in total

1.  A New Preoperative Scoring System for Predicting Aggressiveness of Non-Functioning Pancreatic Neuroendocrine Neoplasms.

Authors:  Tetsuya Takikawa; Kazuhiro Kikuta; Shin Hamada; Kiyoshi Kume; Shin Miura; Naoki Yoshida; Yu Tanaka; Ryotaro Matsumoto; Mio Ikeda; Fumiya Kataoka; Akira Sasaki; Hidehiro Hayashi; Waku Hatta; Yohei Ogata; Kei Nakagawa; Michiaki Unno; Atsushi Masamune
Journal:  Diagnostics (Basel)       Date:  2022-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.